Immunotherapy and targeted therapy review
We help prepare prior treatment history, biomarker results, response information, and questions for specialist discussion.
Advanced oncology pathways
For eligible patients, we can help prepare records and coordinate communication around advanced oncology options. Eligibility and treatment direction must always be assessed by licensed physicians and receiving institutions.
We help prepare prior treatment history, biomarker results, response information, and questions for specialist discussion.
On 22 June 2026, CARsgen announced Chinese approval of satricabtagene autoleucel (satri-cel/CT041), described as the world's first approved CAR-T product for solid tumors. The announced indication is CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after failure of at least two prior treatment lines.
Where clinically relevant, we help families prepare questions about cellular therapy pathways, eligibility, safety, timing, and hospital requirements.
For eligible patients, we can help explore potential clinical research opportunities, prepare documents, understand eligibility requirements, and coordinate communication.
When reassessment suggests surgery may be discussed, we help coordinate communication with appropriate surgical teams.
We turn complex hospital steps into a practical timeline without replacing medical advice.
We do not provide CAR-T or other treatments, determine eligibility, promise access to approved treatment or clinical research pathways, promise clinical trial enrollment, or promise outcomes. We help patients prepare, coordinate, and communicate.
Here for your next step
Tell us where you are and what support your family needs. We will discuss the appropriate records and contact channel with you before you send a full medical file.
Please do not send passport copies or a full medical file in your first message. Contact local emergency services for urgent medical help.